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1. Introduction 
The incidence of malignant melanoma has increased exponentially in recent decades (Jemal 
et al., 2001). Indeed it has been estimated that the incidence worldwide doubles every 10 to 
15 years (Cascinelli & Marchesini, 1989). The American Cancer Society projected over 38,000 
new cases of melanoma in males and 29,000 in females in 2009 (American Cancer Society, 
2009). Currently, melanoma accounts for 3% of cancer diagnoses annually and although this 
is fewer than the reported incidence of other skin cancers the prognosis is unfortunately 
significantly worse. Melanoma accounts for 2% of cancer deaths in men and 1% in women 
(Boring et al., 1994). Survival is directly related to stage at diagnosis. Recent years have seen 
improvements in overall survival with 87% survival at five years for all patients, and 94% in 
patients with localized disease (Parker et al., 1996; Kopf, 1988). However, survival for 
patients with stage IV disease remains low at 25% at 2 years (Balch et al., 2001). 
Public awareness of melanoma has increased in parallel with this increasing incidence. The 
most important risk factor is intermittent high exposure to ultraviolet radiation. However, 
despite this increasing awareness, the practice of ultraviolet radiation protection behaviour 
is low. Worryingly, in a 2005 survey in the US up to 14% of adults, primarily women and 
young adults, reported the use of indoor tanning devices on at least one occasion (American 
Cancer Society, 2009). 
The mainstay of treatment is surgical excision with intention to cure (Prichard et al., 2002). 
However, the last decade has seen a paradigm shift in the surgical approach to this disease. 
The management of the primary tumour has become more conservative, with acceptance of 
narrower excision margins. Similarly, there has been a move away from the routine 
performance of an elective regional lymph node dissection, towards the utilization of 
sentinel lymph node biopsies to accurately stage the patient’s disease. The purpose of this 
chapter is to highlight the appropriate surgical management of both the primary tumour 
and the associated regional lymph node basin. We also aim to distil current controversies in 
the management of the regional lymph node basin. 
2. Diagnosis 
Any suspicious naevi or skin lesions should be assessed, using either the ABCDE system or 
the 7-point checklist shown below. 
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Seven point checklist: The ABCDE lesion system: 
Major features are:   
Change in size A Geometrical Asymmetry in 2 axes 
Irregular shape B Irregular Border 
Irregular colour C At least 2 different Colours in lesion 
Minor features are: D Maximum Diameter >6 mm 
Largest diameter 7 mm or more E Elevation of lesion 
Inflammation 
Oozing 
Itch/change in sensation  
Table 1. Seven point checklist and ABCDE system for assessment of pigmented lesions 
(Whited, JD et al. 1998) 
2.1 Risk factors 
Risk factors for the development of malignant melanoma are varied and include genetic 
susceptibility, exposure to ultraviolet radiation, and immunologic deficits (Friedman et al., 
1991). The most important of these is intermittent ultraviolet exposure. Intermittent 
unaccustomed sun exposure and sunburn history were found to have considerable roles as 
risk factors for melanoma. Interestingly, they reported that high occupational exposure was 
inversely associated to melanoma (Gandini et al., 2005).  
Epidemiological studies have identified: blue, green or grey eyes, blonde or red hair, light 
complexion, freckles, sun sensitivity, and the inability to tan, as risk factors for the 
development of melanoma (Evans et al., 1988; Gellin et al., 1969). Countries with 
predominantly fair-skinned populations have shown that increasing proximity to the 
equator is associated with an increased risk of developing melanoma. Although it is not 
possible to modify genetic factors, minimizing exposure to ultraviolet radiation, in particular 
intermittent exposure to high intensity radiation, and the adoption of photoprotective 
measures, can significantly reduce the risk of development of melanoma (Brozena, 1993; 
Friedman, 1991). The most commonly practiced sun protection behaviours in a national 
sample of US adults were the application of sunscreen and shade seeking. The use of 
protective clothing (hats and long-sleeved shirts) was less frequently practiced (American 
Cancer Society, 2009)  
Other risk factors for the development of melanoma include: a positive family history 
(Greene et al., 1985) personal history of melanoma or non-melanoma cancer or in-situ skin 
carcinoma (Evans et al., 1988), large numbers of melanoctic naevi in childhood (Holman & 
Armstrong, 1984), and xeroderma pigmentosum (Kraemer, 1984).  
2.2 Biopsy 
Suspicious lesions should undergo a full thickness excisional biopsy (Lees & Briggs, 1991). 
This should include the full thickness of the lesion with a 1- 3 mm margin of clinically 
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normal skin and subcutaneous fat. The surgical incision should be planned with definitive 
treatment in mind. This should include longitudinal orientation in the extremities. In 
addition, narrow excision margins are recommended, in order to avoid interference with 
subsequent sentinel lymph node mapping (Royal College of Surgeons Guidelines, 2006).  
As shave and punch biopsies make pathological staging of melanoma impossible, their 
routine use is not recommended (Royal College of Surgeons Guidelines, 2006). Incisional 
biopsies may also render lesions difficult to assess on histopathological criteria, but they 
may be acceptable in certain anatomic locations such as the palm or sole, digit, face, ear, 
subungal areas, or in very large lesions. Incisional biopsies have not been associated with a 
worse prognosis, in terms of local or regional recurrence rates or mortality (Ledeerman & 
Sober, 1985; Lees & Briggs, 1991; Austin et al., 1996; Royal College of Surgeons, 2006). 
3. Surgical management of the primary tumour  
The surgical management of the primary tumour has shifted from extensive surgical 
resection, which was not only debilitating but also disfiguring, to a more conservative 
approach. Patients with malignant melanoma should ideally be managed by a 
multidisciplinary team in a tertiary referral centre. This team should include: a dermatologist, 
surgeon, medical oncologist, pathologist, radiologist, counsellor, specialist nurse and palliative 
care specialist (Royal College of Surgeons, 2006).  
Excision biopsy of histologically confirmed melanoma should be followed by excision of the 
melanoma scar with a macroscopic margin of normal skin (Royal College of Surgeons, 2006). 
Previously, wider excision margins have been used to prevent lymphatic spread to the 
draining lymph node basin. Numerous studies have, however, failed to show any 
statistically significant difference between wide excision margins ranging from 3 – 5 cm, and 
narrower margins of 1 – 2 cm, in terms of local recurrence, mortality and disease-free 
survival. In addition, wider excision margins are associated with greater morbidity. 
(Thomas et al., 2004). Excision margins around primary melanoma should not be less than 1 
cm. Exception to this rule is made for in-situ melanoma, where confirmed histological 
excision is adequate (Haigh et al., 2003).  
The risk of death from melanoma is dependent on a number of factors, including tumour 
thickness according to the Breslow classification (Breslow, 1980), the presence of ulceration 
in the primary tumour, micrometastases to sentinel nodes, tumour site and gender (Balch et 
al., 2001). As survival is directly dependent on tumour thickness, current guidelines 
recommend excision margins based on Breslow thickness of the initial excision biopsy 
(Royal College of Surgeons, 2006). For patients with T1 tumours, a margin of 1 cm is 
advised. In this group of patients, where melanoma are less than 1 mm thick, rates of local 
recurrence are not higher when an excision margin of 1 cm is used instead of wider margins 
(Veronesi et al., 1977). A 1 – 2 cm excision margin is recommended for T2 lesions. Long-term 
results of a randomised trial have shown that a melanoma greater than 0.8 mm and less than 
or equal to 2 mm thickness can be treated with excision margins of 2 cm, as safely as those 
with 5 cm margins. Rates of local recurrence are not higher in patients with the narrower 2 
cm margin. Similarly, rates of overall survival and recurrence -free survival are not higher in 
patients with narrower resection margins (Cohn-Cedarmark et al., 2000). T3 and T4 lesions 
should have a 20 mm margin. Loco-regional recurrence rates have been shown to be higher 
in melanoma greater than or equal to 2 mm thickness that is excised with a 1 cm margin, 
instead of a 3 cm margin. However, overall survival rates are similar in both groups. There 
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is insufficient data to support the preferred use of either a 2 cm or 3 cm margin, and 
consequently, it may be reasonable to allow the patient to decide, following an informed 
discussion of surgical options. The use of the larger 3 cm margin is however recommended 
in patients with deep tumours (> 4 mm depth), due to the higher risk of loco-regional 
recurrence (Thomas et al., 2004). In selected cases, however, margin size may be modified to 
accommodate individual anatomic or cosmetic considerations (Royal College of Surgeons, 
2006). Table 2 shows a summary of recommended excision margins based on tumour size. 
 
Margins 
Tis Histologically clear margins are adequate
T1 1 cm margin recommended 
T2 1-2 cm margin recommended 
T3&T4 2 – 3 cm margin recommended 
Table 2. Recommended excision margins based on tumour size 
3.1 In-transit metastasis 
In-transit metastases are defined as cutaneous or subcutaneous deposits of melanoma 
between the site of primary disease and regional lymph nodes (Hayes et al., 2004). Deposits 
may be localized around the primary tumour, may be widespread throughout the affected 
limb, or on the head, neck or trunk, depending on the primary site. The number of deposits 
generally increases over time (Hayes et al., 2004). They are thought to arise from 
dissemination of melanoma cells via lymphatics to tissues located primarily between the 
primary tumour and the regional lymph node basin. Other theories include that of drift 
metastases within tissue fluid of the limb (McCarthy, 2002) or the local implantation of 
circulating haematogenous melanoma cells (Heenan & Ghaznawie, 1999).  
The presence of small in-transit metastatic melanoma presents specific surgical problems. 
Unlike nodal disease, which can be managed by regional lymph node dissection (with local 
recurrences being uncommon), in-transit disease is often widespread and may necessitate 
multiple surgeries as the disease progresses and new deposits become apparent. This may 
cause a great deal of distress for patients. In its most severe form, in-transit metastasis may 
become severely disabling and may be refractory to treatment. Treatment is therefore, 
palliative, even if staging investigations fail to show evidence of distant metastatic disease 
(Hayes et al., 2004). Recent studies have recommended that treatment should be tailored to 
the extent of the disease, with treatments associated with significant morbidity being 
reserved for bulky advanced metastases (Hayes et al., 2004). 
In-transit metastases are sharply circumscribed with a clear line demarcating them from 
normal dermis and epidermis. This line does not contain any in-situ component. Therefore, 
wide excision margins are not recommended for these lesions, and, therefore, a complete 
macroscopic excision and primary closure is sufficient. If lesions are grouped closely 
together, an en bloc excision is acceptable (Hayes et al., 2004). 
There are numerous treatments available for management of in-transit metastases that are 
not amenable to surgical excision. Carbon dioxide laser therapy has been used in the 
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management of multiple small in-transit metastases that are not suitable for surgical 
excision. This treatment may be performed under local anaesthetic or if a very large number 
of lesions are present, general anaesthetic. It is suitable for use as a day-case procedure. If 
the lesion is small -measuring less than 3 mm- it may be vapourized completely. Larger 
lesions, however, are first circumscribed with the laser followed by excision of the central 
core. Haemostasis is achieved with a pressure dressing, following treatment. This procedure 
is tolerated well by patients, as it is relatively pain free. Wound healing may take up to 6 
weeks following treatment. The value of carbon dioxide laser therapy is highest in patients 
with multiple small lesions, but is it is less useful in patients with larger deposits. It has been 
recommended that this treatment be undertaken before isolated limb perfusion, as the latter 
is associated with significant morbidity (Hayes et al., 2004).  
Isolated limb perfusion (ILP) was first described in the 1960s (Creech & Krementz, 1966). 
This process involves the application of a tourniquet to the affected limb, thereby isolating it 
from the systemic circulation, and administering cyctotoxic agents via an extracorporeal 
bypass circuit. This procedure is performed under general anaesthetic. The first step is to 
expose and cannulate the artery and vein supplying the affected limb. The chemotherapeutic 
agent is then perfused over a period of 1 hour. Agents used include melphalan and 
dacarbazine. TNF-α has been shown to increase response rates, when given with melphalan 
(Lienard et al., 1992). It is thought to work by targeting neo-vasculature instead of being 
directly cytotoxic to tumour cells, and is of use in larger deposits (Fraker, 1999). This is then 
followed by a washout period lasting 30 minutes (Hayes et al., 2004). Advantages of this 
procedure include the delivery of high doses (up to tenfold higher than the dose tolerated 
systemically) of chemotherapeutic agents to the affected limb, with a reduction in systemic 
toxicity (Briele et al., 1985). Disadvantages of this treatment are numerous: local toxicity may 
be in the form of mild erythema or even epidermolysis and deep tissue damage (Wieberdink 
et al., 1982). High pressures may lead to compartment syndrome requiring fasciotomy 
(Mubarak & Owen, 1977). Hypotension and myelosuppression may result from leakage of 
perfusate into the systemic circulation (Hayes et al., 2004). One study found that patients 
with stage III disease, who were treated with BCG and dimethyltriazeno imidazole 
carboxamide (DTIC), trended towards a delay in recurrence and increased survival, but this 
was not statistically significant (Can Med Assoc J. 1983). Similarly, the use of interferon 
alpha for isolated limb perfusion is not supported by strong scientific evidence (RCSI 
guidelines, 2006). 
More recently, the role of isolated limb infusion in the management of in-transit metastasis 
is being investigated. This technique is minimally invasive, easy to perform and is more 
economical than isolated limb perfusion (Brady et al, 2006; Mian et al, 2001). The size of the 
area treated depends on disease severity and ranges from a small section of a limb to the 
entire limb. The first step in this process is to determine the volume of the limb in order to 
allow calculation of the appropriate dose of chemotherapeutic agents. A number of 
techniques have been described for calculation of limb volume. These include the use of 
programs which take into account serial limb measurements. Other centres use the formula 
πr2h to calculate limb volume at measured intervals. The next step is the placement of 
arterial and venous catheters into the contralateral limb. The catheter tips must lie above the 
knee or elbow. A hot air blanket is placed over the affected limb with the intention in 
inducing a temperature of 38-40 degrees Celcius (limb hyperthermia). The patient is 
anaesthetised and 30ml of papaverine is administered followed by a heparin flush. A 
tourniquet is then applied. A mixture of dactinomycin and melphalan are circulated for 20 
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TNM Staging Categories for Cutaneous Melanoma 
Classification Thickness (mm) Ulceration Status/Mitoses 
Tis NA NA 
T1 ≤ 1.00 a: Without ulceration and mitosis < 1/ mm2 
  b: With ulceration or mitoses ≥1/ mm2 
T2 1.01-2.00 a: Without ulceration 
  b: With ulceration 
T3 2.01-4.00 a: Without ulceration 
  b: With ulceration 
T4 > 4.00 a: Without ulceration 
  b: With ulceration 
N No. of Metastatic Nodes Nodal Metastatic Burden 
N0 0 NA 
N1 1 a: Micrometastasis* 
  b: Macrometastasis† 
N2 2 -3 a: Micrometastasis* 
  b: Macrometastasis† 
  
c: In transit metastases/satellites without 
metastatic nodes 
N3 
4+ metastatic nodes, or 
matted nodes, or in transit 
metastases/satellites with 
metastatic nodes 
 
M Site Serum LDH 
M0 No distant metastases NA 
M1a 
Distant skin, subcutaneous, 
or nodal metastases 
Normal 
M1b Lung metastases Normal 
M1c 
All other visceral 
metastases 
Normal 
 Any distant metastasis Elevated 
Abbreviations: NA, not applicable; LDH, lactate dehydrogenase.  
 Micrometastases are diagnosed after sentinel lymph node biopsy.  
†Macrometastases are defined as clinically detectable nodal  
metastases confirmed pathologically. 
Table 3. TNM staging categories for cutaneous melanoma (Balch et al., 2009) 
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minutes by withdrawing through the venous circuit and infusion into the arterial circuit. 
One litre of Hartmann’s solution is then infused to remove the chemotherapeutic agents. 
Following the infusion the tourniquet and catheters are removed, a pressure dressing is 
applied and the patient’s leg is elevated (Al-Hilli et al, 2007). 
Isolated limb infusion has a number of advantages over isolated limb perfusion. Firstly, it is 
associated with a lower rate of complications including erythema, skin loss, compartment 
syndrome, myopathy, neuropathy and limb loss (1%). In addition, catheters are placed 
percutaneously making it less invasive with no requirement for a bypass circuit. Operating 
time is shorter than for isolated limb perfusion (4 hours for isolated limb perfusion versus 1 
hour for isolated limb infusion). Complete response rates of 45% and partial response rates 
of 42% have been reported for isolated limb infusion compared to complete response rates 
of 40% and partial response rates of 40% for isolated limb perfusion (Brady et al, 2006; Mian 
et al, 2001). 
The presence of in-transit metastases indicates a poor prognosis. The development of in-
transit disease is rapidly followed by distant metastases (Hayes et al., 2004). The American 
Committee on Cancer Staging (AJCC) classify it as stage IIIB or IIIC disease, along with 
regional lymph node metastases. Five year survival rates in patients with stage III disease 
ranges from 18% to 60%. However, patients with in-transit metastasis have the worst 
prognosis, with 5 year survival of approximately 25% (Hayes et al., 2004). 
3.2 Reconstruction 
The optimal treatment of patients is primary closure, following excision of the primary 
tumour with adequate margins. Unfortunately, this is not always possible, and the patient 
may require reconstructive surgery. The type of reconstruction employed depends on the 
location of the melanoma. Skin grafts are often used, following excision of melanoma on the 
limbs. Traditionally, these were harvested from the contralateral limb, as melanoma was 
thought to metastasize primarily via lymphatic routes (Cade, 1961, Roberts et al., 2002). A 
recent study has shown that there is no difference in rates of donor site recurrence whether 
the ipsilateral or contralateral limb is used. The authors recommended that to improve 
patients post-operative recovery, the skin graft be harvested from the same limb as the 
primary tumour (Schumacher et al., 2010).  
The use of skin grafts on the head and neck, however, is not always ideal, and may give rise 
to significant deformity. Local rotational skin flaps, such as rhomboid flaps, are safe, 
versatile, and aesthetically pleasing when used in this area (Lent & Aryian, 1994). They may 
also be of use in very large areas where a skin graft alone would give a poor cosmetic result.  
4. Management of the regional lymph node basin  
The outcome in patients diagnosed with melanoma is dependent, not only on tumour 
thickness, but also on the presence of regional or distant metastasis (Lees & Briggs, 1991). In 
fact, regional lymph node status is thought to be the most powerful prognostic indictor in 
clinically localized melanoma (Morton et al., 2006). The presence of regional nodal 
metastasis is associated with a 50% reduction in survival (Royal College of Surgeons, 2006). 
The rate of nodal metastatic disease is largely dependant upon the initial tumour thickness. 
T1 melanoma has a favourable outlook, with a 10% risk of occult nodal metastasis. 
Approximately 25% of patients, with melanoma between 1.5 - 4.0 mm thick, have lymph 
node metastasis at presentation. 60% of patients with melanoma greater than 4 mm will 
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show regional lymph node metastasis at diagnosis. These data form the basis for the current 
guidelines on which patients should be offered a sentinel lymph node biopsy (Royal College 
of Surgeons, 2006). 
Patients diagnosed with stage III disease commonly have clinically negative lymph nodes 
but are found to have micro-metastatic disease on their sentinel lymph node biopsy. Such 
patients have a more favourable outcome than patients with clinically involved nodes at 
presentation (Balch et al., 2009). The major determinants of outcome for stage III disease are: 
number of metastatic lymph nodes and the presence of either microscopic or macroscopic 
disease. Five-year survival rates for patients with stage IIIA disease is 67%, and 10-year 
survival is 60%. Five-year survival rates for patients with stage IIIB disease is estimated at 
53%. Stage IIIC disease has a poorer prognosis with 5-year survival of approximately 26% 
(Balch et al., 2001). 
5. The sentinel lymph node biopsy 
The sentinel lymph node is defined as any lymph node that receives lymphatic drainage 
directly from a primary tumor site (Thompson, 2001; Uren et al., 1994). The rationale for 
undertaking a sentinel lymph node biopsy in melanoma is to firstly to provide prognostic 
information and secondly to allow node negative patients avoid an unnecessary lymph node 
dissection. The current indications for sentinel lymph node biopsy include intermediate 
thickness melanoma, 1 – 4 mm (Morton et al., 2006). However, a study published this year 
also recommended that patients with thin melanoma, greater than 0.75 mm and or 
ulceration, should be considered for a sentinel lymph node dissection, although this has as 
yet not gained widespread acceptance (Yonick et al., 2011). 
The use of sentinel lymph node biopsy allows surgeons to appropriately select patients for 
complete lymph node dissection, instead of undertaking lymph node dissection in all 
patients. This practice allows assessment of the regional lymph node basin with low rates of 
morbidity (Gershenwald et al., 1999). By managing occult nodal metastases early, through 
sentinel lymph node dissection, the patients risk of melanoma-related death is reduced 
(Faries et al., 2010).  
 
 
Fig. 1. The sentinel lymph node biopsy 
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The technical details of sentinel lymph node biopsy can be broken down into a number of 
steps. First, the patient undergoes preoperative lymphoscintigraphy which identifies the 
regional nodal basin and estimates the location of the sentinel node. Four intradermal 
injections of 0.1–0.2 ml of 10 mBq radiocolloid are performed around the melanoma or 
melanoma scar: the injection should raise a small wheal on the skin. The most commonly 
used radiotracers are 99mTc-labeled albumin (Europe), 99mTc-labeled sulfur colloid and 
99mTc-antimony trisulfide colloid. Scintillation cameras are used to obtain dynamic images. 
These images allow identification of sentinel nodes within the regional nodal basin. They 
also allow discrimination of second-tier nodes, which may be falsely interpreted as sentinel 
nodes on delayed imaging. The surface location of the sentinel node may be marked on the 
skin preoperatively or, alternatively, a gamma probe can be use to locate the node intra-
operatively. Intra-operative lymphatic mapping involves injection of vital blue dye (Isosulfan 
blue (Lymphazurin), Methylene Blue or Patent Blue V are used). A combination of radiotracers 
and blue dye has been shown to allow sentinel node identification in 99% of cases. The blue 
dye is injected intra-dermally (again to produce a wheal) in 2-4 locations at the site of the 
primary lesion, 10-15 minutes before skin incision. The dye is used to visualize the sentinel 
node intra-operatively. A gamma probe (covered in a sterile plastic sheath), which detects 
radiation, may be used to locate the sentinel node. Counts should be obtained over the skin 
before incision, to confirm the location of the sentinel node. A short skin incision is made, 
bearing in mind the potential need for complete lymph node dissection. The sentinel nodes 
are then identified using the blue dye and gamma probe as a guide, and they are removed 
with minimal dissection. An ex-vivo count should be obtained, by measuring the radioactivity 
of the sentinel node(s) after removal. A bed count is then also obtained following removal of 
the sentinel node(s), to ensure that no sentinel nodes remain (Bagaria et al., 2010). 
 
 
Fig. 2. Gamma probe used to locate sentinel lymph node 
Significant controversy surrounds the use of sentinel lymph node biopsy in thin, early 
melanomas. There are a number of reasons for this. Firstly, patients with a low-risk of nodal 
metastases are exposed to the toxicity of a potentially unnecessary procedure. Secondly, the 
routine use of sentinel lymph node biopsy is expensive: global application of sentinel lymph 
node biopsy in all patients is estimated to cost between $700,000 and $1,000,000 for every 
sentinel node metastasis detected (Agnses et al., 2003). 
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Can we therefore use the sentinel lymph node technique selectively in patients with thin 
melanomas? Multiple studies have examined risk factors for poor prognosis in patient with 
thin melanoma. Age has been shown to be associated with a decreased overall and 
melanoma-specific survival (Faries et al., 2010). Paradoxically, age is associated with a lower 
risk of lymph node metastases. This paradox can be explained by decreased lymphatic 
function with advancing age (Conway et al., 2009). Other risk factors which have been put 
forward as predictors of lymph node metastasis include: sex, vertical growth phase, Breslow 
thickness, mitotic rate, Clark level, and tumour-infiltrating lymphocytes (Bedrosian et al., 
2000; Bleicher et al., 2003; Cecchi et al., 2007; Gimotty et al., 2004; Kesmodel et al., 2005; 
Oliveira et al., 2003; Puleo et al., 2005; Vaquerano et al., 2006).  
These specific factors remain controversial and several studies have questioned their 
importance (Stitzenberg et al., 2004; Wong et al., 2006). The use of vertical growth phase as a 
predictor of metastasis may be problematic as it is not reported in many centres and 
pathologists may not be experienced at distinguishing it from the radial growth phase. A 
similar problem is encountered when Clark level is used (Owen et al., 2001). Tumour-
infiltrating lymphocytes are measured on a scale that is deemed to be subjective, and 
therefore may give rise to inter-observer variation. Mitotic rate, however, has been shown to 
be extremely important in melanoma risk assessment (Gimotty et al., 2005; Paek et al., 2007; 
Sondak et al., 2004) and is planned to be included in the updated American Joint Committee 
on Cancer Staging system. Ulceration has been associated with a worse prognosis and a 
higher rate of nodal metastasis, but this is an uncommon finding in thin lesions (McKinnion 
et al., 2003). A recent study by Faries et al, examining the rate of nodal recurrence in thin 
melanoma following wide local excision, only identified Breslow thickness, age, and sex as 
significant indicators of recurrence. Based on these findings, they developed a scoring 
system and nomogram for the risk of regional nodal metastasis. It has been recommended 
that this system may be used to reassure low-risk patients, who are anxious about 
metastasis, or to convince high-risk patients to proceed with a sentinel lymph node biopsy 
(Faries et al., 2010).  
The role of sentinel lymph node biopsy for patients with thick melanomas (> 4 mm) also 
remains controversial. This specific group of patients have a high risk of nodal metastasis, 
with some studies showing rates as high as 60% (Balch et al., 2001; Gershenwald et al., 2000). 
However, as this group of patients are also at high risk of distant metastatic disease the role 
of either sentinel lymph node biopsy or regional lymph node clearance remain unclear, in 
terms of providing an improvement in overall survival. Recent studies, have however 
proposed an improvement in both disease free and overall survival with the presence of a 
negative sentinel lymph node (Scoggins et al., 2010). They therefore concluded that sentinel 
lymph node biopsy and complete lymph node dissection for sentinel node positive patients 
achieves good regional nodal disease control. Sentinel lymph node biopsy in this group of 
patients may, therefore important for prognosis as well as having therapeutic implications 
and should at least be considered in these patients (Scoggins et al., 2010).  
6. Elective regional lymph node dissection  
Complete lymph node dissection is performed with the intention of halting metastatic 
spread of melanoma in the early stages of the disease (Callery et al., 1982; Roses et al., 1985). 
Five-year survival rates in patients with negative complete lymph node dissection stands at 
62.5%, compared with 20.3% in patients with positive non-sentinel nodes (Kunte et al., 
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2009). Therefore, patients undergoing elective lymph node dissection should have improved 
survival, when compared with patients who are only treated following the appearance of 
metastases, a point that has been demonstrated in numerous retrospective studies (Balch et 
al., 1979, 1988; Callery et al., 1982; Milton et al., 1982; Roses et al., 1985). Before the advent of 
sentinel lymph node biopsy, a complete lymph node dissection was carried out for all 
patients with malignant melanoma irrespective of lymph node status. However, a number 
of randomized prospective trials have failed to show overall survival benefit to elective 
lymph node dissection, and propose that regional lymph nodal metastases represent 
markers of systemic disease (Balch et al., 1996; Sim et al., 1978; Veronesi et al., 1977, 1982).  
It is unclear if an elective lymph node dissection is the appropriate next step in the 
management of patients with a positive sentinel lymph node biopsy. Currently, a complete 
lymph node dissection is carried out for all patients with a positive sentinel lymph node, 
irrespective of the type of metastases (micro-metastasis or macro-metastasis). The value of a 
complete lymph node dissection in this group of patients has not been extensively 
investigated (Garbe et al., 2008) and it must constantly be borne in mind that complete 
lymph node dissection is associated with significant patient morbidity (Guggenheim et al., 
2008). 
A significant survival benefit has been noted in patients with a positive sentinel lymph node 
biopsy, who undergo a complete lymph node dissection, when compared with patients 
undergoing complete lymph node dissection after nodal metastases become apparent 
(Kretschmer et al., 2004). In a study conducted by Morton et al. (2006), a 5-year survival rate 
of 72% was seen in patients with positive sentinel lymph nodes, followed by immediate 
lymph node dissection, whereas patients undergoing a delayed lymph node dissection had 
a 5-year survival rate of only 52%. However, further positive non-sentinel lymph nodes are 
found in a relatively small proportion of patients: previously quoted figures ranged from 
17%-24% (Ghaferi et al., 2009; Lee et al., 2004; Rossi et al., 2008; Wright et al., 2010). 
However, a recent study has shown rates of further positive findings to be as low as 14.8% 
(Kunte et al., 2011).  
Ideally, patients at high risk of non-sentinel nodal metastases could be identified and treated 
by regional lymph node dissection, and patients with a low risk of non-sentinel nodal 
metastases could be spared from further intervention (Wright et al., 2008). Recently, 
researchers have sought to identify factors, which increase a patient’s likelihood of non-
sentinel node metastases. Increasing Breslow depth has been associated with increased risk 
of non-sentinel node metastases, while a depth of less than 1 mm has no association with 
any further positive nodes on completion lymph node dissection (Kunte et al., 2011). Studies 
have failed to show an association between specific tumour and patient characteristics with 
an increased rate of non-sentinel nodal metastasis (Rossi et al., 2008). However, a number of 
histopathologic features have been shown to be associated with positive complete lymph 
node dissections. These include: nodular melanoma, ulceration, melanoma regression, 
naevus association, and no special tumour characteristics (Kunte et al., 2011). Using a 
size/ulceration score, Reeves et al. (2003) showed ulceration to be an independent predictor 
of non-sentinel node deposits.  
Recent studies have examined the association between the size of sentinel lymph node 
deposits and the rate of positive complete lymph node dissection. Kunte et al. (2011) did not 
report any patients with micro-metastatic deposits on sentinel lymph node biopsy to have 
positive findings on complete lymph node dissection (Glumac et al., 2008). Another study 
showed a 3-year survival rate in patients with 1 mm sentinel lymph node metastasis to be 
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100%, while 3-year survival in patients with deposits greater than 1 mm was 80% (Van der 
Ploeg et al., 2009). Ollila et al. (2009), however, found a significantly higher rate of 
recurrence in patients with sub-micrometastatic disease (ie. sentinel lymph node deposits 
less than 0.1 mm), compared with node-negative patients. Unfortunately the role of 
complete lymph node dissection in patients with a positive sentinel lymph node biopsy 
remains unclear and further study is necessary to identify factors which may be 
incorporated into a model for assessing risk of identifying high risk patients. 
7. Conclusion 
The incidence of melanoma is rising steadily in the Western world. Increased awareness of 
the disease has not impacted on its poor prognosis. Surgery remains the mainstay of 
treatment for this difficult tumour. Indeed there is little in the way of adjuvant systemic 
therapy that improves overall survival. Adequate surgical margins with or without local 
reconstructive techniques can improve local recurrence rates. Utilization of the sentinel node 
biopsy technique allows accurate staging of disease and determination of prognosis. 
Positive sentinel lymph nodes should be treated with regional lymph node dissection to 
reduce loco-regional disease. The impact of this on overall survival has not yet been clearly 
elucidated. The future lies in the continued expansion of the molecular basis of melanoma 
and the hope of personalised targeted molecular therapies.  
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